Today it was the turn of fast-growing pharmaceutical company Mayne Pharma Group Ltd (ASX: MYX) to hold its annual general meeting.
Although its shares may have edged lower, I believe today's presentation once again reiterates why Mayne Pharma is one of the best shares to buy and hold in the industry.
The company has had an explosive start to FY 2017 thanks partly to the acquisition of the portfolio of generic drugs from Teva Pharmaceutical. For the first four months of the new financial year Mayne Pharma has seen sales growth of 104% on the prior corresponding period to $172 million.
A key driver in the strong start has been its U.S. Generic Products Division. So far in FY 2017 sales in the segment are up a whopping 352% to US$97 million.
The company's Dofetilide product has been the star of the show. Dofetilide is the generic alternative to Tikosyn, an anti-arrhythmic agent used to treat irregular heartbeats such as atrial fibrillation and atrial flutter.
Dofetilide accounted for 16% of sales during the period and according to management has become the market leader in respect to volume share following its successful launch.
Elsewhere the Metrics Contract Services and Mayne Pharma International segments performed well with sales up 23% and 14% respectively year to date .
The same can't be said for the Specialty Brands Division which has seen sales dip by 44% year to date. This is the result of destocking in the trade channel following the loss of exclusivity on 50mg and 200mg dosages of the Doryx antibiotic.
Pleasingly the launch of two key dermatology products in early 2017 means that management expects a much stronger second half to the year.
All in all I believe the company looks set to have yet another fantastic year and is a great alternative to industry giant CSL Limited (ASX: CSL).
With Mayne Pharma's shares changing hands at just 17x estimated FY 2017 earnings according to CommSec, it looks to be an absolute bargain in my eyes.
Though it is worth noting that the company is still under investigation from the U.S. Department of Justice for price fixing. Management doesn't believe any penalties imposed will be material to earnings, but investors with a low tolerance for risk may want to wait for a decision to be made before investing.
